Paediatric drug optimisation and prioritisation
Why prioritisation is needed
Prioritisation is a necessary first step to enable a targeted approach to research and development, alongside the development and updating of normative guidance on the use of medicines to treat and prevent communicable and noncommunicable diseases. WHO leads and convenes this work in collaboration with appropriate stakeholders active in each disease area.
Why do we need paediatric drug optimisation?
- Clinical research is lengthy and expensive, so efforts should target compounds with the highest chances of addressing people’s needs.
- Developing formulations for children may require expensive technologies; efforts should target those with the highest impact.
- The market for medicines for children is often small and/or fragmented, resulting in limited volumes and potential market failures.
- The market for medicines for children is often small and/or fragmented, resulting in limited volumes and potential market failures.
Research and development efforts need to be streamlined and targeted at the products that are most needed.
Prioritising disease areas
With the ever-accelerating pace of scientific discovery, changing burdens of disease and availability of resources, prioritization of activities must have a regular cadence and a structured methodology. To achieve this, GAP-f will regularly evaluate and prioritize its focus using the following lenses

Research and development efforts need to be streamlined and targeted at the products that are most needed.
Align funders, procurers, market-coordination entities, researchers, innovators, generic manufacturers, product development partnerships and regulators around priority products and a clear research agenda for future drug optimization for children.
Foundational work
To better understand the paediatric medicines landscape and identify unmet needs across therapeutic areas, WHO, through GAP-f, conducted a comprehensive review of the formulations listed in the Model List of Essential Medicines for Children (EMLc). Using a dedicated assessment tool, the review examined how well the listed formulations met the needs of children of different ages, including whether they allowed flexible dosing and could be administered easily.
The findings informed additions, removals and revisions adopted in the 2023 and 2025 editions of the EMLc, helping countries and procurement agencies select age-appropriate formulations. The review also clarified where suitable formulations were still lacking across disease areas, helping to identify priorities for paediatric medicines development.
Read more about the formulation review below.
Towards closing the gap in access to child-friendly formulations of essential medicines
Methodology
Paediatric drug optimisation follows a standard, stepwise approach tailored to each disease area to reflect its medicines pipeline and programme needs. It assesses children’s prevention and treatment needs, the suitability of existing quality-assured formulations, and barriers to access and supply. It then applies defined criteria to establish access, priority and watch list, and identifies the evidence needed to guide product development, regulatory approval, access and appropriate use.
Further details on the methodology are available in this publication.
Paediatric drug optimization standard procedure
Final outputs of PADO processes
PADO access list
1–2 years
|
PADO priority list
3–5 years
|
PADO watch list
5–10 years
|
|---|---|---|
Contains medicines and formulations that have already been developed, approved by regulatory authorities and recommended by WHO, but for which access and uptake remain limited. Goal
Accelerate access, uptake and rollout of priority products through targeted advocacy and coordinated actions, identifying specific activities and opportunities for engagement wherever possible. |
Contains priority paediatric formulations requiring development, specifying dosage forms and strengths where known. Selection criteria
Goal
Advocate for and enable accelerated development of priority formulations, guiding R&D efforts towards unmet needs. |
Contains medicines, formulations and regimens with potential pediatric benefit requiring further investigation and development. Selection criteria
Goal
Encourage early paediatric consideration and guide research priorities, promoting integration into adult pipelines. |
Drug optimization research agenda
The PADO process identifies key research priorities to address evidence gaps and inform the development and optimization of medicines for children. These may include pharmacokinetic and safety studies; modelling and simulation to inform dose optimisation and weight-band dosing; development of age-appropriate formulations and delivery systems; generation of efficacy data where extrapolation from adults is not appropriate; assessment of drug–drug interactions, feasibility, acceptability and palatability; and investigation of long-term safety, pharmacovigilance, drug resistance and treatment durability.
Disease-area PADO priorities
Each area below is reviewed through a WHO-convened Paediatric Drug Optimization (PADO) exercise. Select one to see its meeting reports, target product profiles and papers, and where every product sits on the access, priority and watch lists.